Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Merck & Co.
Tulathromycin
Другие языки:

Tulathromycin

Подписчиков: 0, рейтинг: 0
Tulathromycin
Tulathromycin.png
Clinical data
Trade names Draxxin, others
AHFS/Drugs.com International Drug Names
Routes of
administration		 Intramuscular, subcutaneous
ATCvet code
Legal status
Legal status
Identifiers
  • (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[[2,6-dideoxy-3-C-methyl-3-Ο-methyl-4-C-[(propylamino)methyl]-α-L-ribo-hexopyrano-syl]oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]-oxy]-1-oxa-6-azacyclopentadecan-15-one
CAS Number
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard 100.166.454
Chemical and physical data
Formula C41H79N3O12
Molar mass 806.092 g·mol−1
3D model (JSmol)
  • CCCNCC1(C(OC(CC1(C)OC)OC2C(C(C(CC(NC(C(C(C(OC(=O)C2C)CC)(C)O)O)C)C)(C)O)OC3C(C(CC(O3)C)N(C)C)O)C)C)O
  • InChI=1S/C40H77N3O12/c1-15-17-41-21-40(49)27(8)52-30(20-38(40,10)50-14)54-32-24(5)34(55-36-31(44)28(43(12)13)18-23(4)51-36)37(9,47)19-22(3)42-26(7)33(45)39(11,48)29(16-2)53-35(46)25(32)6/h22-34,36,41-42,44-45,47-49H,15-21H2,1-14H3/t22-,23-,24+,25-,26-,27+,28+,29-,30+,31-,32+,33-,34-,36+,37-,38-,39-,40+/m1/s1 checkY
  • Key:HWATWVYEWMIMSO-FROLMUNOSA-N checkY

  • InChI=1S/C41H79N3O12/c1-15-17-42-22-41(50)28(8)53-31(20-39(41,10)51-14)55-33-25(5)35(56-37-32(45)29(44(12)13)18-24(4)52-37)38(9,48)19-23(3)21-43-27(7)34(46)40(11,49)30(16-2)54-36(47)26(33)6/h23-35,37,42-43,45-46,48-50H,15-22H2,1-14H3/t23-,24-,25+,26-,27-,28+,29+,30-,31+,32-,33+,34-,35-,37+,38-,39-,40-,41+/m1/s1
  • Key:GUARTUJKFNAVIK-QPTWMBCESA-N
  (verify)

Tulathromycin, sold under the brand name Draxxin among others, is a macrolide antibiotic used to treat bovine respiratory disease in cattle and swine respiratory disease in pigs.

Medical uses

Tulathromycin is indicated for:

Cattle: Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis sensitive to tulathromycin.

Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis sensitive to tulathromycin.

Pigs: Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis, and Bordetella bronchiseptica sensitive to tulathromycin.

Sheep: Treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent Dichelobacter nodosus requiring systemic treatment.

Society and culture

Legal status

Tulathromycin (brand name Draxxin) was approved for medical use in the European Union in November 2003.

Tulathromycin (brand names Tulissin and Tulaven) was approved for medical use in the European Union in April 2020.

On 16 July 2020, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted positive opinions, recommending the granting of marketing authorizations for the veterinary medicinal products Increxxa and Tulinovet solutions for injection for cattle, pigs and sheep. The applicant for Increxxa is Elanco GmbH. The applicant for Tulinovet is VMD N.V. Increxxa was approved for veterinary use in the European Union in September 2020.

Brand names

It is marketed by Pfizer Inc. under the brand name Draxxin.

It is marketed by Bimeda Inc. under the brand name Macrosyn, and by Merck & Co. under the brand name Arovyn.

It is also sold under the brand name Increxxa.

External links



Новое сообщение